Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2025-12-24 @ 11:04 PM
NCT ID:
NCT03189069
Eligibility Criteria:
Inclusion Criteria:
* Had at least 1 pharmacy claim for warfarin, apixaban, dabigatran, or rivaroxaban during the identification period (01-Jan-2013 through 31-Dec-2015)
* Had continuous health plan enrollment with medical and pharmacy benefits for 6 months pre-index date (baseline period)
* Had continuous health plan enrollment with medical and pharmacy benefits for at least 1 month following index date
* Had at least 1 medical claim for atrial fibrillation any time before or on index date
Exclusion Criteria:
* Had medical claims with a diagnosis code for rheumatic mitral valvular heart disease, mitral valve stenosis or heart valve replacement/transplant during the 6-month baseline period
* Had medical claims with a diagnosis code for dialysis, kidney transplant, or end-stage chronic kidney disease during the 6 month baseline period
* Had medical claims indicating a diagnosis of venous thromboembolism during the 6-month baseline period
* Had claims indicating a diagnosis or procedure code of hip or knee replacement surgery within 6 weeks prior to the index date
* Had claims for a diagnosis or procedure code for reversible atrial fibrillation
* Had medical claims indicating pregnancy during the study period
* Had a pharmacy claim for warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban during the 6-month baseline period
* Had \> 1 oral anticoagulant prescription claim on the index date
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03189069
Study Brief:
Protocol Section:
NCT03189069